Nectar Life Sciences Limited — Cefixime Exporter Profile
Indian Pharmaceutical Exporter · #8 for Cefixime · $4.4M export value · DGFT Verified
Nectar Life Sciences Limited is the #8 Indian exporter of Cefixime with $4.4M in export value and 184 verified shipments. Nectar Life Sciences Limited holds a 2.5% market share in Cefixime exports across 19 countries. The company exports 3 pharmaceutical products worth $13.3M across 1 therapeutic categories.
Nectar Life Sciences Limited — Cefixime Export Profile: Buyers & Destinations
Where Does Nectar Life Sciences Limited Export Cefixime?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED ARAB EMIRATES | $1.3M | 62 | 25.2% |
| TANZANIA | $863.0K | 34 | 17.0% |
| MEXICO | $660.3K | 28 | 13.0% |
| NETHERLANDS | $593.4K | 27 | 11.7% |
| MALTA | $314.9K | 15 | 6.2% |
| ROMANIA | $286.4K | 10 | 5.6% |
| SERBIA AND MONTENEGRO | $276.1K | 6 | 5.4% |
| MYANMAR | $125.6K | 8 | 2.5% |
| IVORY COAST | $123.5K | 3 | 2.4% |
| ETHIOPIA | $80.6K | 2 | 1.6% |
Nectar Life Sciences Limited exports Cefixime to 23 countries. The largest destination is UNITED ARAB EMIRATES accounting for 25.2% of Nectar Life Sciences Limited's Cefixime shipments, followed by TANZANIA (17.0%) and MEXICO (13.0%). These destinations reflect Nectar Life Sciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Cefixime from Nectar Life Sciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| JILICHEM (T) LIMITED | TANZANIA | $654.3K | 29 |
| IDA TRADING MEA C/O KUEHNE + NAGEL | UNITED ARAB EMIRATES | $411.0K | 21 |
| NORTIS ALLIANCE FZCO | UNITED ARAB EMIRATES | $346.5K | 12 |
| IMPERIAL MEDICAL SOLUTIONS FZE | UNITED ARAB EMIRATES | $226.0K | 18 |
| IMRES B V | NETHERLANDS | $210.9K | 7 |
| JILICHEM T LIMITED | TANZANIA | $208.8K | 5 |
| IDA MEA KUEHNE + NAGEL LLC | UNITED ARAB EMIRATES | $193.3K | 4 |
| VRK EXPEDITIONS SRL | ROMANIA | $161.7K | 4 |
| HEMOFARM VRSAC | SERBIA AND MONTENEGRO | $150.0K | 3 |
| PRODUCTOS FARMACEUTICOS S A DE C V | MEXICO | $148.4K | 4 |
Nectar Life Sciences Limited supplies Cefixime to 60 buyers globally. The largest buyer is JILICHEM (T) LIMITED (TANZANIA), followed by IDA TRADING MEA C/O KUEHNE + NAGEL (UNITED ARAB EMIRATES) and NORTIS ALLIANCE FZCO (UNITED ARAB EMIRATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Cefixime Export Value and How Much Does Nectar Life Sciences Limited Contribute?
India exported $61.9M worth of Cefixime through 8,398 shipments from 668 suppliers to 131 countries, serving 1,805 buyers globally. Nectar Life Sciences Limited contributes $4.4M to this total, accounting for 2.5% of India's Cefixime exports. Nectar Life Sciences Limited ships Cefixime to 23 countries through 60 buyers.
What Is the Average Shipment Value for Nectar Life Sciences Limited's Cefixime Exports?
Nectar Life Sciences Limited's average Cefixime shipment value is $23.7K per consignment, based on 184 shipments totaling $4.4M. The largest destination is UNITED ARAB EMIRATES (25.2% of Nectar Life Sciences Limited's Cefixime exports).
How Does Nectar Life Sciences Limited Compare to Other Indian Cefixime Exporters?
Nectar Life Sciences Limited ranks #8 among 668 Indian Cefixime exporters with a 2.5% market share. The top 3 exporters are MICRO LABS LIMITED ($19.1M), AUROBINDO PHARMA LTD ($8.0M), SAKAR HEALTHCARE LIMITED ($4.5M). Nectar Life Sciences Limited processed 184 shipments to 19 destination countries.
What Cefixime Formulations Does Nectar Life Sciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CEFIXIME TABLETS USP 400 MG (IDA Code 50 | $193.3K | 4 |
| FIXINECT 400 MG CEFIXIME TABLETS 400 MG | $150.0K | 3 |
| CEFAPAN 400MGCEFIXIME 400MG FILM COATED | $150.0K | 3 |
| FIXINECT 400 MG (CEFIXIME TABLETS 400 MG) REG NO. TZ 18 H 0013, BATCH NOS -TITD24004 TO TITD24011, MFG. DATE | $144.3K | 3 |
| CEFIXIME TABLETS USP 400 MG BATCH NOS : IMTC23009 TO IMTC23015 MFG. DATE : DEC.2023 EXP. DATE : NOV.2026NOS | $123.7K | 3 |
| FIXINECT 400 MG CEFIXIME TABLETS 400 MGREG NO TZ 18 H 0013 BATCH NOS TITD23001 TITD23004 MFG DATE FEB 2023 E | $100.0K | 2 |
| FIXINECT CEFIXIME TABLETS USP 200MG 1X10 IFTB23002 TO IFTB23004 M.OCT-2023E.SEP-2026 | $100.0K | 2 |
| CEFIXIME TABLETS USP 400 mg (IDA Code 5027-BL1-TB-NCT-09A) BATCH NOS : IETC24031 TO IETC24033 MFG. DATE : 11/2024 EXP. D | $100.0K | 2 |
| CEFIXIMA 400 MG (CEFIXIME 400 MG FILM COATED TABLES) BATCH NO.SETD24001 MFG DT.MAR-2024 EXP DT.FEB-2026 | $97.9K | 3 |
| FIXINECT 400 MG (CEFIXIME TABLETS 400 MG) REG NO. TZ 18 H 0013 (BATCH NOS- TITD23015 TO TITD23019 MFG. DATE-DEC.2023 EXNOS | $95.3K | 3 |
Nectar Life Sciences Limited exports 153 distinct Cefixime formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CEFIXIME TABLETS USP 400 MG (IDA Code 50 with 4 shipments worth $193.3K.
Regulatory Requirements: Exporting Cefixime to Key Markets
What Nectar Life Sciences Limited must comply with to export Cefixime to its top destination countries
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Nectar Life Sciences Limited Compare to Nearest Cefixime Exporters?
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | AUROBINDO PHARMA LTD | $8.0M | 192 | 6 | $41.6K |
| 5 | SAKAR HEALTHCARE LIMITED | $4.5M | 91 | 11 | $50.0K |
| 8 | NECTAR LIFE SCIENCES LIMITED ★ | $4.4M | 184 | 19 | $23.7K |
| 2 | LUPIN LIMITED | $4.2M | 83 | 4 | $50.0K |
| 9 | CAPLIN POINT LABORATORIES LIMITED | $3.5M | 98 | 8 | $35.5K |
Nectar Life Sciences Limited ranks #8 among 668 Indian Cefixime exporters. Average shipment value of $23.7K compared to the market average of $92.6K. The closest competitors by value are AUROBINDO PHARMA LTD and SAKAR HEALTHCARE LIMITED.
Which Indian Ports Ship Cefixime Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 924 | 11.0% |
| JNPT | 498 | 5.9% |
| JNPT/ NHAVA SHEVA SEA | 480 | 5.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 449 | 5.3% |
| SAHAR AIR | 412 | 4.9% |
| DELHI AIR CARGO ACC (INDEL4) | 399 | 4.8% |
| DELHI AIR | 366 | 4.4% |
| AHEMDABAD ICD | 226 | 2.7% |
What Other Advanced Antibiotics Products Does Nectar Life Sciences Limited Export?
Nectar Life Sciences Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Nectar Life Sciences Limited's Cefixime Exports
The current geopolitical landscape presents significant challenges for Indian pharmaceutical exporters like Nectar Life Sciences Limited. The Israel-Iran conflict has led to disruptions in Middle East trade routes, particularly affecting the Red Sea and Suez Canal. These disruptions have resulted in increased shipping costs and extended transit times, posing risks to the timely delivery of pharmaceutical products. The Pharmaceutical Export Promotion Council of India (Pharmexcil) estimates potential losses ranging from ₹2,500 crore to ₹5,000 crore due to these supply chain issues.
In the United States, recent tariff implementations have introduced additional complexities. In August 2025, the U.S. imposed broad tariffs on imports from over 60 countries, including India, with rates reaching up to 39%. These tariffs have significantly impacted Indian pharmaceutical exports, as the U.S. is a major market for generic drugs. The Federation of Indian Export Organisations highlighted that nearly 55% of India's exports to the U.S. are affected, leading to concerns about competitiveness and market access.
Conversely, the India–EFTA Trade and Economic Partnership Agreement (TEPA), effective from October 2025, offers a positive development. This agreement aims to eliminate or reduce tariffs on goods traded between India and EFTA countries (Iceland, Liechtenstein, Norway, and Switzerland), potentially opening new avenues for Indian pharmaceutical exports. However, compliance with stringent EU regulations, such as the Falsified Medicines Directive, remains a critical factor for market entry.
Nectar Life Sciences Limited — Regulatory Compliance & Quality Standards
The regulatory environment for Indian pharmaceutical exporters is becoming increasingly stringent. The U.S. Food and Drug Administration (FDA) has intensified inspections, with over 200 conducted in 2023 and plans to increase this number in 2024. Compliance with Good Manufacturing Practices (GMP) is paramount, as non-compliance can lead to import alerts and suspension of product registrations.
Nectar Life Sciences Limited's recent regulatory setbacks, including the AEMPS' Statement of Non-Compliance and the environmental penalty imposed by the National Green Tribunal, underscore the importance of robust quality assurance systems and environmental compliance. Addressing these issues is crucial for the company to maintain and expand its export markets.
About Nectar Life Sciences Limited
Nectar Life Sciences Limited exports 3 products worth $13.3M. Beyond Cefixime, top products include Ceftriaxone, Cefuroxime. View the complete Nectar Life Sciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Cefixime — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Cefixime shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Nectar Life Sciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 235 individual customs records matching Nectar Life Sciences Limited exporting Cefixime, covering 153 formulations to 23 countries via 60 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 131+ countries, 1,805+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Cefixime Export Data from Nectar Life Sciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Nectar Life Sciences Limited's Cefixime exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Nectar Life Sciences Limited
Full Company Profile →
3 products · $13.3M total trade · 1 categories
Cefixime Stats
Company Overview
Top Products by Nectar Life Sciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Nectar Life Sciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Cefixime. For current shipment-level data, contact TransData Nexus.